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Background
Normal cellular metabolism is altered in cancer cells,
shifting away from the TCA cycle towards glycolysis,
increasing glucose consumption and lactate production.
This key characteristic change in metabolism is termed
the Warburg effect. Importantly, HPV 16 E7 oncoprotein
alters the function pyruvate kinase type M2, increasing
glucose consumption and lactate production. Clinically,
increased lactate production in head and neck cancers is
associated with a decreased response to therapy. Cancers
with high lactate production have a poor five year survi-
val, approximately 40% worse than similar tumors with
low lactate production. Lactate has also recently been
shown to disrupt functions of key immune cells (CD8
and DC’s) in vitro. We have recently shown that an
immune response is required to clear HPV+ head and
neck squamous cell carcinomas (HNSCC) in vivo.I nt h i s
project we tested the hypothesis that lactate within the
tumor microenvironment inhibits immune mediated
clearance of HPV+ cancers.
Material and methods
Experiments were completed in culture on human and
mice HPV+ cancer lines, in a preclinical mouse model of
HPV+ cancer and a human phase 2 clinical trial initiated.
Results
We show that human and mouse HPV+HNSCC’sh a v e
enhanced lactate production. Inhibition of lactate with
either Dichloroactetate (DCA) or Oxamate decreases
tumor cell growth in colony forming assays. DCA-
mediated lactate inhibition in vivo was well tolerated,
decreased tumor lactate levels, increased tumor pH. DCA
treatment by itself did not alter tumor growth significantly.
However, to test whether it would enhance immune
related clearance during cisplatin/radiation, studies in
immune competent mice were completed and compared
to identical studies in immune deficient (RAG1) mice. The
studies show that inhibition of lactate production resulted
in enhanced immune mediated clearance during treatment
with cisplatin and radiation therapy. Furthermore, siRNA-
mediated knock down of lactate dehydrogenase (LDH)
confirmed the role of LDH and epithelial cell lactate pro-
duction in this response. These findings show that altered
metabolism and decreasing lactate in the tumor microen-
vironment not enhances immune clearance during ther-
apy. Due to these finding a phase 2 clinical trial has been
initiated which combines DCA with cisplatin/radiation.
The initial results from the trial will be presented.
Conclusion
Tumor produced lactate attenuates the immune clear-
ance of HPV+ cancers. Decreasing this lactate and thus
enhancing immune clearance may be very relevant for
immune suppressed HIV+ individuals during therapy.
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